PANTUMOR 1479-0009

222730

ANV600-001

PRIMROSE (D9970C00001)

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1).



<ul class="wp-block-list">
<li>Code NKI: M24ANV</li>



<li>Code firm: ANV600-001</li>



<li>Code clinicaltrials.gov: NCT06470763</li>
</ul>



Principal Investigator



Dr. N. Steeghs



Drugs 



ANV600 (bispecific antibody against PD1 and IL2 as monotherapy and in combination with Pembrolizumab).



<h2 class="wp-block-heading">Summary</h2>



The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.



Read more on <a href="https://clinicaltrials.gov/study/NCT06470763">clinicaltrials.gov.</a>